Drug Profile
Pertussis acellular vaccine - BioNet Asia/Mahidol University
Alternative Names: Pertagen; Viaskin® rPT; Viaskin®-PTLatest Information Update: 19 Jul 2022
Price :
$50
*
At a glance
- Originator BioNet-Asia; Mahidol University
- Developer BioNet-Asia; DBV Technologies; University of Geneva
- Class Bacterial vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pertussis
Most Recent Events
- 17 Jun 2022 BioNet-Asia initiates enrolment in a clinical trial for Pertusis in Switzerland
- 01 Jul 2020 Phase-II/III clinical trials in Pertussis (Prevention) in Australia (IM) (ACTRN12619000944134)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Pertussis(Prevention) in Switzerland (Transdermal, Patch)